

Invitation to the presentation of Cantargia's H1 2025 report

Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) will publish the company's interim report for the first six months of 2025 on Thursday, August 21, 2025, at 07:00 a.m. CEST.

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on August 21, at 3:00 p.m. CEST, where Cantargia's interim CEO Damian Marron, CBO Ton Berkien, and CFO Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session.

If you wish to participate via audiocast, please use the link below. Via the web session you will be able to ask written questions. Webcast: <https://cantargia.events.inderes.com/q2-report-2025>.

If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

<https://events.inderes.com/cantargia/q2-report-2025/dial-in>.

The webcast will also be available on demand on Cantargia's corporate website: www.cantargia.com.

For further information, please contact

Damian Marron, Interim CEO

Telephone: +46 (0)46-275 62 60

E-mail: damian.marron@cantargia.com

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.



PRESS RELEASE
12 August 2025 10:15:00 CEST

Attachments

Invitation to the presentation of Cantargia's H1 2025 report